Relief Therapeutics Holding AG (RLFTF)

[djhfsu]

Need some help from smarter people than me.

I'm trying to better understand the mechanics of the blinded study. Based on today's news announcement of no futility or safety concerns and company's plan to continue to 165 patients, what does that indicate:

1. If the company continues on the journey to 165 patients, can the FDA still stop the study early and get this drug to all hospitals BEFORE the readout of top line results in Jan?

2. If the answer is "No" to #1 above, does that indicate this drug may only be "good" and not great for this critical covid patient population?

I'm in for a sizeable position and didn't sell any shares during the sell-off...in fact, but a few more. I like the quality of people involved with the company and all the breadcrumbs along the way.

Appreciate any thoughts from the smarter people : )

Thanks,
Dave